Sep 14, 2022 / 02:50PM GMT
Evan Arthur Stover - Robert W. Baird & Co. Incorporated, Research Division - Senior Research Associate
We're going to get started. My name is Evan Stover. I cover pharma services and health care supply chain with Baird. We're pleased to have Catalent with us this morning. We have CFO, Tom Castellano and Paul Surdez, IR. Tom is going to kick it off with some prepared remarks, and then we'll go into fireside.
Thomas P. Castellano - Catalent, Inc. - Principal Accounting Officer, Senior VP & CFO
Thanks, Evan. Appreciate it. Thanks, everyone, for the time and the opportunity. Before we get into the fireside chat, I think there's just a couple of key points that I wanted to make sure we reinforced here to the investment community. First, we're coming off of our fiscal '22 year. We're in a year that ends on June 30, one of the strongest financial years we've had as a company, record revenue and EBITDA. We saw a 20% revenue growth during our fiscal '22, 28% adjusted EBITDA growth during the period.
Similarly, our Q4 results were very robust as well, and
Catalent Inc at Robert W Baird Global Healthcare Conference Transcript
Sep 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers